Congress strips insurers' power to delay care—doctors decide now

What it does

This bill prohibits health insurance plans (private and federal) from requiring prior authorization, step therapy, or medical necessity reviews before covering treatments. Doctors and patients would decide on care; insurers cannot delay or deny coverage based on pre-approval requirements. The ban applies to all covered services starting January 1, 2026.

Why we flagged it

The bill's operative mechanism is a blanket prohibition on three insurer cost-control tools (prior authorization, step therapy, medical necessity review). It is not a subsidy, carve-out, or narrow exemption — it is a broad restriction on insurer power applied uniformly across all covered services and all plan types.

What the text implies

• Eliminates insurer ability to enforce step-therapy (fail-first) protocols, which currently require patients to try cheaper drugs before accessing more expensive ones; this may increase drug costs and total plan spending.
• Removes medical necessity reviews, which currently allow insurers to deny coverage for off-label uses or experimental treatments; patients gain access but plans lose a tool to exclude unproven therapies.
• Prior authorization removal may increase emergency-department utilization and uncoordinated care if patients bypass referral pathways; no care-coordination mechanism replaces the authorization process.
• Federal health care programs (Medicare, Medicaid, FEHBP) face identical restrictions; this may increase federal spending and shift cost pressure to beneficiary cost-sharing or provider reimbursement cuts.
• No carve-out for fraud prevention or safety reviews; insurers cannot require authorization for high-risk or high-cost procedures even when clinical evidence is weak.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Patients and doctors regain autonomy over treatment decisions without insurer delays or denials. Prior authorization is a documented source of treatment delays, medical errors, and patient harm; removing it reduces administrative friction and restores clinical judgment. The trade-off is that insurers lose cost-control tools, which may increase premiums, but the bill's direct effect on individual patients is access expansion.

Who stands to gain

• pharmaceutical companies (step-therapy removal increases drug utilization)
• specialty care providers (fewer authorization barriers to referral)
• medical device manufacturers (medical necessity reviews eliminated)
• patients with chronic or complex conditions (reduced access delays)

Named in the bill

Health insurance issuers, Group health plans, Federal health care programs, Medicare, Medicaid, Federal Employees Health Benefits Program (FEHBP), Public Health Service Act (Title XXVII), Social Security Act (Section 1128B)

Where it stands

• Jan 22, 2025 — Introduced · Congress.gov: “Introduced in House”
• Jan 22, 2025 — Referred to House Committee on Oversight and Government Reform and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Oversight and…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

2 lobbying clients named this bill on 3 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $3,110,000 in lobbying spend. A filing names 6 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 41% of bills with at least one filing.

Jefferson Van Drew, the sponsor, reported $386,700 in PAC receipts in the 2026 cycle.

• America's Health Insurance Plans Inc (ahip) — $3,010,000 on 1 filing
• American College of Radiology Association — $100,000 on 2 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.